VitaDX and MEDIPATH collaborate to deploy VisioCyt® , an innovative solution for the early diagnosis of bladder cancer

Publishing
VitaDX and MEDIPATH collaborate to deploy VisioCyt® , an innovative solution for the early diagnosis of bladder cancer
Partager cet article
VitaDX and MEDIPATH collaborate to deploy VisioCyt® , an innovative solution for the early diagnosis of bladder cancer
Texte

VitaDX is proud to announce its partnership with Medipath, a group of independant pathologists specialized in locally based diagnostics and expertise in oncology.
This collaboration enables the deployement of VisioCyt®, our first innovative solution for the diagnosis and folow-up of bladder cancer, relying on artificial intelligence and image processing : valuable tool for urologists and their patients suffering from this pathology (5th most frequent cancer in France).


Précédent
Suivant